MarketCapExport financials
Tekla Life Sciences Investors (HQL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramTekla Life Sciences Investors Financial Ratios 2020-2011 | HQL
Brief overview of Tekla Life Sciences Investors's valuation multiples
Ratios are assessed across five available annual reports in the 2011–2014 interval.
The latest available valuation ratios are P/E 5.09x (median 3.86x), P/B 1.02x (median 0.95x), P/CF 30.04x (median 10.19x). On average, this basket is 31.7% above its own five-year medians. The market is pricing in elevated future expectations.
Earnings yield calculated as 1/P/E is about 19.7%, showing current profit per unit of share price.
The latest available business-quality ratios are ROE 20.1%, ROA 20.1%. Business quality is high on return ratios, supporting the ability to create value.
PEG of 0.68x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
Banks and insurers require sector-specific reading: the value and return on capital matter more than standard industrial multiples.
Conclusion
Tekla Life Sciences Investors demonstrates high business quality but trades at a premium to its own history. Strong future results are needed to preserve valuation.
Annual Financial Ratios Tekla Life Sciences Investors
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | - | - | - | - | - | 5.1 | 3.4 | 2.8 | 4.4 |
P/S |
- | - | - | - | - | - | 515.9 | 548.9 | 100.5 | 286.0 |
EV/EBITDA |
- | - | - | - | - | - | 2.5 | 1.7 | 1.4 | 4.4 |
PEG |
- | - | - | - | - | - | -0.3 | 0.68 | 0.03 | 0.01 |
P/B |
- | - | - | - | - | - | 1.0 | 0.9 | 0.9 | 1.0 |
P/CF |
- | - | - | - | - | - | -8.6 | 30.0 | 10.2 | 1.4 |
ROE % |
- | - | - | - | - | - | 20.10 | 28.00 | 34.18 | 21.96 |
ROA % |
- | - | - | - | - | - | 20.07 | 27.96 | 34.12 | 21.84 |
DSO |
- | - | - | - | - | - | 41.5 | 70.2 | 34.1 | 512.3 |
DPO |
- | - | - | - | - | - | 8.8 | - | - | 72.5 |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Tekla Life Sciences Investors, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Russia
